Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 38 (31), 5987-6001

Identification of a Novel EphB4 Phosphodegron Regulated by the Autocrine IGFII/IR A Axis in Malignant Mesothelioma

Affiliations

Identification of a Novel EphB4 Phosphodegron Regulated by the Autocrine IGFII/IR A Axis in Malignant Mesothelioma

Pierluigi Scalia et al. Oncogene.

Abstract

Malignant mesothelioma is a deadly disease with limited therapeutic options. EphB4 is an oncogenic tyrosine kinase receptor expressed in malignant mesothelioma as well as in a variety of cancers. It is involved in tumor microenvironment mediating angiogenesis and invasive cellular effects via both EphrinB2 ligand-dependent and independent mechanisms. The molecular network underlying EphB4 oncogenic effects is still unclear. Here we show that EphB4 expression in malignant mesothelioma cells is markedly decreased upon neutralization of cancer-secreted IGF-II. In particular, we demonstrate that EphB4 protein expression in malignant mesothelioma cells depend upon a degradation rescue mechanism controlled by the autocrine IGF-II-insulin receptor-A specific signaling axis. We show that the regulation of EphB4 expression is linked to a competing post-translational modification of its carboxy-terminal tail via phosphorylation of its tyrosine 987 by the Insulin receptor isoform-A kinase-associated activity in response to the autocrine IGF-II stimuli. Neutralization of this autocrine-induced EphB4-phosphorylation by IGF-II associates with the increased ubiquitination of EphB4 carboxy-terminal tail and with its rapid degradation. We also describe a novel Ubiquitin binding motif in the targeted region as part of the identified EphB4 phosphodegron and provide 3D modeling data supporting a possible model for the acute EphB4 PTM-driven regulation by IGF-II. Altogether, these findings disclose a novel molecular mechanism for the maintenance of EphB4-expression in malignant mesothelioma cells and other IGF-II-secreting cancers (IGF2omas).

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Oncogene. 1999 Apr 15;18(15):2471-9 - PubMed

References

    1. Cancer Res. 2007 Oct 15;67(20):9800-8 - PubMed

References

    1. Hepatology. 2008 Jul;48(1):146-56 - PubMed

References

    1. Cell. 1996 Aug 9;86(3):353-64 - PubMed

References

    1. J Cell Biochem. 2001;82(4):610-8 - PubMed

References

    1. Proc Natl Acad Sci U S A. 2002 May 28;99(11):7455-60 - PubMed

References

    1. Biochem J. 2009 Aug 27;422(3):433-42 - PubMed

References

    1. Proteins. 2006 Nov 15;65(3):712-25 - PubMed

References

    1. BMC Cancer. 2013 May 30;13:269 - PubMed

References

    1. Cancer Res. 1998 Jan 15;58(2):348-51 - PubMed

References

    1. J Chem Phys. 2007 Jan 7;126(1):014101 - PubMed

References

    1. EMBO J. 2006 Feb 8;25(3):628-41 - PubMed

References

    1. Dev Biol. 1997 Sep 1;189(1):33-48 - PubMed

References

    1. Mol Endocrinol. 2011 Aug;25(8):1456-68 - PubMed

References

    1. Methods Mol Biol. 2017;1558:41-55 - PubMed

References

    1. Int J Cancer. 2012 Sep 1;131(5):E614-24 - PubMed

References

    1. Nucleic Acids Res. 2015 Jan;43(Database issue):D512-20 - PubMed

References

    1. J Cell Physiol. 2013 Apr;228(4):675-9 - PubMed

References

    1. Int J Cancer. 2015 Apr 15;136(8):1781-91 - PubMed

References

    1. J Biol Chem. 1994 May 13;269(19):13779-84 - PubMed

References

    1. J Biol Chem. 2002 Oct 18;277(42):39684-95 - PubMed

References

    1. Cancer Res. 2005 Jun 1;65(11):4623-32 - PubMed

References

    1. Tumour Biol. 2013 Feb;34(1):379-85 - PubMed

References

    1. Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):128-137 - PubMed

References

    1. Cell Res. 2016 Apr;26(4):399-422 - PubMed

References

    1. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5823-7 - PubMed

References

    1. Cell. 1998 May 29;93(5):741-53 - PubMed

References

    1. Endocrinology. 2011 Mar;152(3):922-30 - PubMed

References

    1. Clin Cancer Res. 2005 Jun 15;11(12):4305-15 - PubMed

References

    1. Nat Rev Cancer. 2010 Mar;10(3):165-80 - PubMed

References

    1. J Biol Chem. 1994 May 13;269(19):14211-8 - PubMed

References

    1. Cancer Res. 1995 Aug 15;55(16):3634-9 - PubMed

References

    1. Genes Dev. 1999 Feb 1;13(3):295-306 - PubMed

References

    1. Transl Oncol. 2018 Aug;11(4):971-978 - PubMed

References

    1. Nat Cell Biol. 2006 Aug;8(8):815-25 - PubMed

References

    1. Cell. 2005 Oct 21;123(2):291-304 - PubMed

References

    1. Nat Commun. 2017 Feb 10;8:14399 - PubMed

References

    1. Nat Struct Biol. 1999 Jan;6(1):44-9 - PubMed

References

    1. Endocr Rev. 2013 Dec;34(6):798-826 - PubMed

References

    1. Oncogene. 2002 Nov 28;21(54):8240-50 - PubMed

References

    1. J Biol Chem. 2002 Nov 15;277(46):43830-5 - PubMed

References

    1. Mol Cell Biol. 1999 May;19(5):3278-88 - PubMed

References

    1. Clin Cancer Res. 1999 Jul;5(7):1935-44 - PubMed

References

    1. Mol Cell. 2007 Dec 14;28(5):730-8 - PubMed

References

    1. Cell Adh Migr. 2014;8(4):294-307 - PubMed

References

    1. Nature. 1994 Jun 2;369(6479):414-8 - PubMed

References

    1. Cell. 2017 Apr 20;169(3):470-482.e13 - PubMed

References

    1. FASEB J. 2005 Oct;19(12):1689-91 - PubMed

References

    1. Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7704-9 - PubMed

References

    1. Angiogenesis. 2010 Sep;13(3):259-67 - PubMed

References

    1. Cell Growth Differ. 1990 Jul;1(7):325-31 - PubMed

References

    1. Cancer Res. 2009 May 1;69(9):3736-45 - PubMed

References

    1. Ear Nose Throat J. 2003 Nov;82(11):866, 869-70, 887 - PubMed

References

    1. J Biol Chem. 2006 Oct 27;281(43):32574-86 - PubMed

References

    1. Sci Rep. 2015 Jun 15;5:10641 - PubMed

Publication types

Feedback